Quality of Life in Patients With Inoperable Malignant Bowel Obstruction

Phase 2

Terminated

Conditions: Intestinal Obstruction

Interventions: Drug: lanreotide (Autogel formulation)

Registration Number: NCT02365584

Lead Sponsor: Ipsen

Brief Summary: The primary objective of the study is to evaluate the impact on quality of life of Lanreotide Autogel 120 mg in combination with standard care, in comparison to the standard care alone, in subjects affected by inoperable malignant bowel obstruction.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 43

Inclusion Criteria

Subjects must demonstrate willingness to participate in the study and to be compliant with any protocol procedure.
Provision of written informed consent prior to any study related procedure.
Diagnosis of an inoperable malignant bowel obstruction, confirmed by appropriate imaging report.
In case of peritoneal carcinomatosis, diagnostic confirmation by CT or MRI scan.
Confirmed as inoperable after medical advice.
Patient with a nasogastric tube or presenting with 3 or more episodes of vomiting every day in the last consecutive 48 hours.
Patient life expectancy must be more than 14 days.

Exclusion Criteria

Has operable obstruction or any sub-obstruction.
Has bowel obstruction due to a non-malignant cause; (hypokaliaemia, drug side-effects, renal insufficiency, etc).
Has signs of bowel perforation.
Has prior treatment with somatostatin or any analogue within the previous 60 days.
Has a known hypersensitivity to any of the study treatments or related compounds.
Is likely to require treatment during the study with somatostatin or any analogue other than the study treatment.
Is at risk of pregnancy or lactation, or is likely to father a child during the study. Females of childbearing potential must provide a negative pregnancy test at start of study and must be using oral or double barrier contraception. Non childbearing potential is defined as post-menopause for at least 1 year, surgical sterilisation or hysterectomy at least three months before the start of the study.
Has any mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.
Has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the subject's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Standard care and Lanreotide Autogel	lanreotide (Autogel formulation)	Standard care according to site clinical practice and Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.

Primary Outcome Measures

Name	Time	Method
Least Squares (LS) Mean Area Under Curve (AUC) of Edmonton Symptom Assessment System (ESAS) Total Scores Collected for the First 7 Days; Full Analysis Set (FAS)	Baseline (Day 1, before randomisation), Days 2, 3, 4, 5, 6 and 7.	Quality of Life was assessed using ESAS, evaluating 9 common symptoms in cancer patients: pain, activity, nausea, depression, anxiety, drowsiness, appetite, well-being and shortness of breath. Symptom severity is rated 0-10 on a numerical scale (0=symptom absent; 10=worst severity). ESAS total score is sum of the 9 items (min score=0, max score=90). Low scores indicate good quality of life; high scores indicate strong discomfort. Questionnaire assessments by the patient or by nurse/caregiver in case of patient's physical inability. AUC is area under the line which joins the points defined by plotting ESAS total score on vertical axis and time values on horizontal axis, computed using trapezoidal rule. Primary endpoint was analysed using the FAS. LS mean AUC of ESAS total scores during first 7 days is presented.

Secondary Outcome Measures

Name	Time	Method
Mean Change From Baseline in Performing General Activity (Karnofsky Performance Status [KPS]); ITT Population	Baseline (Day 1, before randomisation) and Days 7, 14 and 28.	The KPS allows patients to be classified as to their functional impairment and was used to assess general activity. KPS scores range from 0 (dead) to 100 (normal/no disease) and are classified as 0-40 = unable to care for self; 50-70 = unable to work; 80-100 = able to work. The lower the KPS score, the worse the survival for most serious illnesses. Scores were recorded on the patient's medical file at each study visit (Days 1, 7, 14 and 28). Mean change from baseline of KPS score at Days 7, 14 and 28 is presented for the ITT population (all randomised patients); a negative change indicates a worsening condition.
Mean Change From Baseline in Daily Intensity of Abdominal Pain Score (Visual Analogue Scale [VAS]); ITT Population	Baseline (Day 1, before randomisation) and Days 7, 14 and 28.	Abdominal pain was assessed using the VAS numeric pain distress scale which is a 100-millimetre (10-centimetre) scoring scale on which patients mark their perceived level of pain. Scores range from 0 to 100 where 0=no pain and 100=unbearable pain. Higher scores indicate a worse outcome. Scores were recorded on the Patient Diary daily until the end of study (Day 28), by the patient or filled in by the nurse/caregiver in case of patient's physical inability. Mean change from baseline of VAS for abdominal pain at Days 7, 14 and 28 is presented for the ITT population; a positive change indicates a worsening condition.
Mean Daily NGT Secretion Volume, in Patients With a NGT	Baseline (Day 1, before randomisation) and Days 7, 14 and 28.	NGT presence and related secretion volume were recorded on the Patient Diary daily until the end of study (Day 28), by the patient or filled in by the nurse/caregiver in case of patient's physical inability. Mean daily secretion volumes, in patients with NGT, is presented.
Mean Change From Baseline in ESAS Total Score; FAS	Baseline (Day 1, before randomisation) and Days 7, 14 and 28.	Quality of Life was assessed using ESAS, evaluating 9 common symptoms in cancer patients: pain, activity, nausea, depression, anxiety, drowsiness, appetite, well-being and shortness of breath. Symptom severity is rated 0-10 on a numerical scale (0=symptom absent; 10=worst severity). ESAS total score is sum of the 9 items (min score=0, max score=90). Low scores indicate good quality of life; high scores indicate strong discomfort. Questionnaire assessments by the patient or by nurse/caregiver in case of patient's physical inability. Secondary endpoints were analysed using the ITT population but to permit following the FAS which was used for primary endpoint analysis, ESAS total score results are reported for both the ITT and the FAS. Mean change from baseline of ESAS total score at Days 7, 14 and 28 is presented here for the FAS; a positive change indicates a worsening condition.
Mean Change From Baseline in Single ESAS Items Symptom Scores; ITT Population	Baseline (Day 1, before randomisation) and Days 7, 14 and 28.	Quality of Life was assessed using ESAS, evaluating 9 common symptoms in cancer patients: pain, activity, nausea, depression, anxiety, drowsiness, appetite, well-being and shortness of breath. Symptom severity is rated 0-10 on a numerical scale (0=symptom absent; 10=worst severity). Low scores indicate good quality of life; high scores indicate strong discomfort. Questionnaire assessments by the patient or by nurse/caregiver in case of patient's physical inability. Mean change from baseline of each individual ESAS item score at Days 7, 14 and 28 is presented; a positive change indicates a worsening condition.
Mean Change From Baseline in Number of Daily Vomiting Episodes; ITT Population	Baseline (Day 1, before randomisation) and Days 7, 14 and 28.	Vomiting episodes were recorded on the Patient Diary daily until the end of study (Day 28), by the patient or filled in by the nurse/caregiver in case of patient's physical inability. Mean change from baseline in number of daily vomiting episodes is presented for the ITT population.
Mean Change From Baseline in ESAS Total Score; ITT Population	Baseline (Day 1, before randomisation) and Days 7, 14 and 28.	Quality of Life was assessed using ESAS, evaluating 9 common symptoms in cancer patients: pain, activity, nausea, depression, anxiety, drowsiness, appetite, well-being and shortness of breath. Symptom severity is rated 0-10 on a numerical scale (0=symptom absent; 10=worst severity). ESAS total score is sum of the 9 items (min score=0, max score=90). Low scores indicate good quality of life; high scores indicate strong discomfort. Questionnaire assessments by the patient or by nurse/caregiver in case of patient's physical inability. Secondary endpoints were analysed using the ITT population but to permit following the FAS which was used for primary endpoint analysis, ESAS total score results are reported for both the ITT and the FAS. Mean change from baseline of ESAS total score at Days 7, 14 and 28 is presented here for the ITT population; a positive change indicates a worsening condition.
Number of Patients Experiencing ≤ 2 Vomiting Episodes/Day During at Least 3 Consecutive Days, in Patients Without NGT	From Baseline (Day 1, before randomisation) to Days 7, 14 and 28.	Vomiting episodes and NGT presence were recorded on the Patient Diary daily until the end of study (Day 28), by the patient or filled in by the nurse/caregiver in case of patient's physical inability. Number of patients experiencing ≤ 2 vomiting episodes/day during at least 3 consecutive days, in patients without NGT, is presented.
Assessment of Passage of Stools; ITT Population	From Baseline (Day 1, before randomisation) to Day 28.	Passage of stools assessments (Yes/No) were recorded on the Patient Diary daily until the end of study (Day 28), by the patient or filled in by the nurse/caregiver in case of patient's physical inability.

Trial Locations

Locations (13): Ospedale Sacro Cuore di Gesù - Fatebenefratelli
🇮🇹
Benevento, Italy
Ospedale San Raffaele IRCCS, Ginecologia oncologica
🇮🇹
Milano, Italy
Ospedali riuniti Ancona- Dipartimento Medicina Interna - Clinica Oncologica
🇮🇹
Ancona, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori - Struttura Complessa di Cure Palliative, Terapia del Dolore e Riabilitazione
🇮🇹
Milano, Italy
Hospice Convento delle Oblate
🇮🇹
Firenze, Italy
I.R.C.C.S. Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (I.R.S.T.) srl
🇮🇹
Meldola, Italy
A.R.N.A.S. P.O. Civico Benfratelli - Oncologia Medica
🇮🇹
Palermo, Italy
Centro di Riferimento Oncologico - di Aviano, Dip. di Oncologia Chirurgica- S.O.C. di Chirurgia Oncologica Generale
🇮🇹
Aviano, Italy
Ospedale Sacro Cuore di Gesù, U.O.C. Oncologia Medica
🇮🇹
Gallipoli, Lecce, Italy
Istituto Tumori "Giovanni Paolo II"- Istituto di Ricovero e Cura a Carattere Scientifico, U.O.C. DI ONCOLOGIA MEDICA
🇮🇹
Bari, Italy
Azienda Sanitaria Locale n ° 5 "Spezzino" Ospedale Felettino - Oncologia Via del Forno 4
🇮🇹
La Spezia, Italy
Azienda Ospedaliero - Polo Universitario "Luigi Sacco"
🇮🇹
Milano, Italy
Azienda Ospedaliera Regionale San Carlo- Oncologia Medica
🇮🇹
Potenza, Italy